脂肪性肝炎
脂肪肝
脂肪变性
肝硬化
内科学
内分泌学
线粒体
生物
细胞生物学
医学
疾病
作者
Susanne Seitz,Yun Kwon,Götz Hartleben,Julia Jülg,Revathi Sekar,Natalie Krahmer,Bahar Najafi,Anne Loft,Sofiya Gancheva,Kerstin Stemmer,Annette Feuchtinger,Martin Hrabě de Angelis,Timo D. Müller,Matthias Mann,Matthias Blüher,Michael Roden,Mauricio Berriel Díaz,Christian Behrends,Jérôme Gilleron,Stephan Herzig
出处
期刊:Nature metabolism
[Nature Portfolio]
日期:2019-10-14
卷期号:1 (10): 1009-1026
被引量:35
标识
DOI:10.1038/s42255-019-0124-x
摘要
Non-alcoholic fatty liver disease (NAFLD) represents a key feature of obesity-related type 2 diabetes with increasing prevalence worldwide. To our knowledge, no treatment options are available to date, paving the way for more severe liver damage, including cirrhosis and hepatocellular carcinoma. Here, we show an unexpected function for an intracellular trafficking regulator, the small Rab GTPase Rab24, in mitochondrial fission and activation, which has an immediate impact on hepatic and systemic energy homeostasis. RAB24 is highly upregulated in the livers of obese patients with NAFLD and positively correlates with increased body fat in humans. Liver-selective inhibition of Rab24 increases autophagic flux and mitochondrial connectivity, leading to a strong improvement in hepatic steatosis and a reduction in serum glucose and cholesterol levels in obese mice. Our study highlights a potential therapeutic application of trafficking regulators, such as RAB24, for NAFLD and establishes a conceptual functional connection between intracellular transport and systemic metabolic dysfunction. Non-alcoholic steatohepatitis (NASH) is characterized by lipid accumulation within hepatocytes and fibrosis. Seitz et al. show that the GTPase protein Rab24 is increased in the livers of people who are obese or have NASH.
科研通智能强力驱动
Strongly Powered by AbleSci AI